China Resources Pharmaceutical Group Limited (3320) held its first extraordinary general meeting of 2026 on 6 February 2026, where shareholders considered an ordinary resolution related to continuing connected transactions under the Sales Framework Agreement 2026/2028, as well as a special resolution to adopt new Articles of Association.

The ordinary resolution was approved by a poll with 1,420,245,890 votes in favor (99.99%) and 50,502 votes against (0.01%). In accordance with the circular, CRH (Pharmaceutical) Limited and Commotra Company Limited, both wholly-owned by China Resources (Holdings) Company Limited (“CR Holdings”), abstained from voting due to a material interest in the Sales Framework Agreement 2026/2028. After the abstention, the total number of shares that could vote on this resolution totaled 2,927,723,849.

The special resolution on the adoption of the new Articles of Association was likewise passed, receiving 4,353,365,002 votes in favor (99.99%) and 50,500 votes against (0.01%). The total number of issued and fully paid-up shares of China Resources Pharmaceutical Group Limited was 6,282,510,461 shares as of the date of the EGM.

All details regarding these resolutions can be found in the company’s circular dated 20 January 2026, which is available on the company’s website and that of the Hong Kong Stock Exchange.